e-learning
resources
Madrid 2019
Monday, 30.09.2019
Pleural disease: applying the evidence
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Heterogeneous delivery of definitive interventions in malignant pleural effusions – results from a Danish survey.
U. Bodtger (Næstved, Denmark), K. Armbruster (Copenhagen, Denmark), S. Skaarup (Aarhus, Denmark), H. Kirstein (Aalborg, Denmark), C. Laursen (Odense , Denmark)
Source:
International Congress 2019 – Pleural disease: applying the evidence
Session:
Pleural disease: applying the evidence
Session type:
Thematic Poster
Number:
3088
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
U. Bodtger (Næstved, Denmark), K. Armbruster (Copenhagen, Denmark), S. Skaarup (Aarhus, Denmark), H. Kirstein (Aalborg, Denmark), C. Laursen (Odense , Denmark). Heterogeneous delivery of definitive interventions in malignant pleural effusions – results from a Danish survey.. 3088
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of solitary fibrous tumours of the pleura: a systematic review and meta-analysis
Utility of pleural fluid for predictive marker testing in malignant pleural effusion
Massive pleural effusion presented with a very rare multitude of complication
Related content which might interest you:
A Dutch web-survey on management of malignant pleural effusions
Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions
Year: 2011
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Source: Guideline 2020
Year: 2020
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Source: Eur Respir J, 55 (6) 1900953; 10.1183/13993003.00953-2019
Year: 2020
Optimal management of symptomatic malignant pleural effusions: individualised care
Source: Virtual Congress 2021 – Hot news from the pleura
Year: 2021
The necessity of examination of patients with pleural effusions by oncological programme
Source: Eur Respir J 2006; 28: Suppl. 50, 75s
Year: 2006
Are patients with malignant pleural effusions being referred appropriately for surgical intervention?
Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Year: 2008
ERS/EACTS statement on the management of malignant pleural effusions
Source: Guideline 2018
Year: 2018
ERS/EACTS statement on the management of malignant pleural effusions
Source: Eur Respir J, 52 (1) 1800349; 10.1183/13993003.00349-2018
Year: 2018
Ambulatory management of malignant pleural effusions
Source: Eur Respir J 2004; 24: Suppl. 48, 629s
Year: 2004
The impact of multimodal treatment approaches in patients with malignant pleural mesothelioma
Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology
Year: 2010
Early pleural fluid control is warranted to prevent reaccumulation of malignant pleural effusion in oncogene-driven lung cancer
Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding
Year: 2019
Ideal volume sampling in the diagnosis of malignant pleural effusions
Source: Annual Congress 2012 - Clinical issues in malignant pleural effusions
Year: 2012
A comparative study of conventional cytology and cell block method in the diagnosis of malignant pleural effusion.
Source: International Congress 2018 – Lung cancer: new tools for diagnosis and patient assessment
Year: 2018
Blind pleural biopsy in the study of undiagnosed pleural effusion: results and complications
Source: Virtual Congress 2020 – Interventional pulmonology: the pleura and bronchoscopic treatment of emphysema
Year: 2020
Malignant pleural effusions: diagnosis and management
Source: International Congress 2017 – PG5 Pleural disease management
Year: 2017
Malignant pleural effusions: from the diagnosis to the management
Source: International Congress 2015 – ME2 Malignant pleural effusions: from diagnosis to management
Year: 2015
Thoracoscopic evaluation of the effect of tumour burden on the outcome of pleurodesis in malignant pleural effusion
Source: Virtual Congress 2021 – Pleural disease and bronchoscopic lung volume reduction
Year: 2021
Malignant pleural effusion survival prognostication in an Asian population
Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding
Year: 2019
Outcomes of cytology positive malignant pleural effusions; do certain malignancies predispose patients to trapped lung?
Source: International Congress 2019 – Novel approaches to pleural effusion: should I change my practice?
Year: 2019
Predictors of successful pleurodesis for patients with malignant pleural effusions
Source: Eur Respir J 2004; 24: Suppl. 48, 493s
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept